PTC/SB/08s (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unfers of contrars a valid OMB control number.

Remove

US Patent and Trademark Office; US DEPARTMENT OF C Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS con

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number			
	Filing Date		2006-09-07	
	First Named Inventor Mich		hiaki KOIZUMI	
	Art Unit			
	Examiner Name			
	Attorney Docket Number		062981	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number Kind Code ¹ Issue Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear							
	1										
If you wis	h to a	i dd additional U.S. Patei	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	of cited Document		Releva	,Columns,Lines ant Passages or s Appear		
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d button			
				FOREIG	SN PAT	TENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patenter Applicant of cited Document	or	Pages,Columns, where Relevant Passages or Rel Figures Appear		Ţ5
	1	2003-329459	JP		A	2003-11-19	Hakuhodo Inc., et a	al.	Abstract, cited in I	SR	
	2	2002-335479	JP		A	2002-11-22	Matsushita Electric Industrial Co., Ltd.		Abstract, cited in I	ISR	
	3	2003-18546	JP		A	2003-01-17	Tokyo Shibaura Eli Co.	ectric	Abstract, cited in I	ISR	

	Application Number			
NEODIA TION DIOOL COURT	Filing Date		2006-09-07	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Michi		iaki KOIZUMI	
(Not for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attorney Docket Numb	er	062981	

	4	10-322232	JP	A	1998-12-04	Alpine Electronics Inc.	Abstract, cited in the Spec.	-
If you wis	h to a	dd additional Foreig	n Patent Docum	ment citation	information p	lease click the Add butto	n Add	
			NON-P	ATENT LIT	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/off country where published.							Τs
	1	International Searc	h Report of PCT/	JP2005/0038	78, date of mail	ng May 24, 2005		
If you wis	h to a	dd additional non-p	atent literature	document ci	tation informat	ion please click the Add	button Add	
				EXAMINE	R SIGNATUR	E		
Examiner	Signa	ature				Date Considered		
*EXAMIN	ER: Ir	nitial if reference co	nsidered, wheth	er or not cit	ation is in conf	ormance with MPEP 609	Draw line through a	

See Kind Codes of USPTO Patent Documents at xwex_USPTO_CODV or MPEP 961.04. Enter office that assed the document, by the Noveleton (WIPO Standard ST3.). For Lapsanese patent document, the articulation of the year of the right or the Emperor warp rescess the sent annumber of the patent document. If Annual of Courtent by the appropriate symbols as enducated on the document under WIPO Standard ST.16 if possible. Speciant is to place a check mark here if Emploits around the service of the sent annual translation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Fing Date 2006-09-07 Find The Temper Page 14 Find The Tempe

CERTIFICATION STATEMENT

Please see	37 C	FR 1.97	and	1.98 to make	the appropriate	selection(s):
------------	------	---------	-----	--------------	-----------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI.)

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patter office in a counterpart foreign application, nd, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. Sea 7 CFR 137(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
 - None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/William F. Westerman/	Date (YYYY-MM-DD)	2006-09-07
Name/Print	William F. Westerman	Registration Number	29988

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.